Steel & Tube Holdings Ltd. logo

Steel & Tube Holdings Ltd. (STU)

Market Open
11 Aug, 03:45
NZX NZX
NZ$
0. 37
+0
+1.3699%
NZ$
- Market Cap
18.14 P/E Ratio
- Div Yield
60,565 Volume
0 Eps
NZ$ 0.37
Previous Close
Add Transaction
Day Range
0.36 0.37
Year Range
0.32 0.73
Want to track STU and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

STU trading today higher at NZ$0.37, an increase of 1.3699% from yesterday's close, completing a monthly increase of 12.1212% or NZ$0.04. Over the past 12 months, STU stock lost -43.9394%.
STU is not paying dividends to its shareholders.
The last earnings report, released on Feb 23, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Steel & Tube Holdings Ltd. has completed 2 stock splits, with the recent split occurring on Aug 14, 2018.
The company's stock is traded on one exchange.

STU Chart

Steel & Tube Holdings Ltd. (STU) FAQ

What is the stock price today?

The current price is NZ$0.37.

On which exchange is it traded?

Steel & Tube Holdings Ltd. is listed on NZX.

What is its stock symbol?

The ticker symbol is STU.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

Has Steel & Tube Holdings Ltd. ever had a stock split?

Steel & Tube Holdings Ltd. had 2 splits and the recent split was on Aug 14, 2018.

Steel & Tube Holdings Ltd. Profile

Oil, Gas & Consumable Fuels Industry
Energy Sector
Dr. Liisa Hurme Ph.D. CEO
NZX Exchange
NZSUTE0001S5 ISIN
DE Country
3,867 Employees
- Last Dividend
14 Aug 2018 Last Split
- IPO Date

Overview

Orion Oyj is a prominent pharmaceutical company that engages in the development, manufacturing, and marketing of human and veterinary pharmaceuticals, alongside active pharmaceutical ingredients (APIs). Established in 1917, the company has a global presence with operations spanning Finland, Scandinavia, the rest of Europe, North America, and other international markets. Orion Oyj's product portfolio includes prescription drugs, self-care products, and veterinary drugs, as well as providing contract manufacturing services. The company has formed strategic partnerships, such as with Propeller Health to integrate its Easyhaler(R) product portfolio and a research collaboration and license agreement with Amneal Pharmaceuticals, Inc. Its headquarter is located in Espoo, Finland.

Products and Services

  • Prescription Drugs and Self-care Products

    Orion Oyj offers an array of medications for a variety of conditions. Nubeqa is targeted for prostate cancer treatment, Precedex, Dexdor, and Precedex for sedation in medical procedures, and Burana for inflammatory pain. The Divina series addresses menopausal symptoms, Trexan for rheumatoid arthritis and cancer, and Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease. In addition, Biosimilars provide alternatives for rheumatoid arthritis and inflammatory bowel diseases, Simdax treats acute decompensated heart failure, and Fareston for breast cancer. Orion also offers solutions for asthma and chronic obstructive pulmonary disease (COPD) with its Easyhaler products like Salmeterol/fluticasone, Budesonide/formoterol, Formoterol, Budesonide, Beclomet, and Buventol.

  • Veterinary Drugs

    For animal health, Orion develops and markets a range of medications including Bonqat for feline hypertension, Clevor for induced vomiting in dogs, and a selection of sedatives and anesthetics such as Domosedan, Domitor, Antisedan, Dexdomitor, and Domosedan Gel. Sileo, designed for noise aversion in dogs, and Tessie, address other veterinary needs. Orion also acts as a distributor for veterinary drugs produced by other global companies, broadening its portfolio.

  • Active Pharmaceutical Ingredients (APIs)

    Orion Oyj supplies APIs for both generic compounds and proprietary products. Through its sophisticated manufacturing capabilities, the company provides contract manufacturing services to partners globally, specializing in high-quality pharmaceutical ingredients.

  • Partnerships and Collaborations

    Noteworthy partnerships include the collaboration with Propeller Health to integrate smart technology with Orion’s Easyhaler(R) line for improved treatment of respiratory conditions. Furthermore, Orion's agreement with Amneal Pharmaceuticals, Inc. facilitates the commercialization of Amneal's generic products, expanding Orion's portfolio and strengthening its market position.

Contact Information

Address: Orionintie 1A, Espoo, Finland, 02200
Phone: 358 10 4261